Stock Scorecard



Stock Summary for Gilead Sciences Inc (GILD) - $88.15 as of 11/20/2024 4:07:39 PM EST

Total Score

9 out of 30

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for GILD

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for GILD

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for GILD

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for GILD

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for GILD (64 out of 90)

Stock Price Rating (Max of 10) 9
Historical Stock Price Rating (Max of 10) 8
Stock Price Trend (Max of 10) 9
Book Value (Max of 10) 5
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 5
Dividend Yield Percentage (Max of 10) 6
Operating Margin (Max of 10) 6
Trading Volume (Max of 10) 10
Price to Earnings (Max of 10) 1

Latest News for for GILD

GSK Drug for Rare Disease-Related Itch Meets Goal in Phase III Study 11/20/2024 4:00:00 PM
ACRS Stock Up on Licensing Deal With Biosion for Two Immunology Drugs 11/19/2024 2:19:00 PM
Eyenovia Stock Tumbles on Termination of Phase III Myopia Study 11/18/2024 2:49:00 PM
ALNY Reports Sustained 6-Month Efficacy Data From Amyloidosis Study 11/18/2024 2:26:00 PM
Cassava Sciences Appoints Freda Nassif as Chief Commercial Officer 11/18/2024 1:30:00 PM
Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024 11/17/2024 3:30:00 PM
Gilead Unveils Long-Term Data From Seladelpar In Patients With Rare Liver Disease - Gilead Sciences ( NASDAQ:GILD ) 11/15/2024 7:14:00 PM
Trump's Victory Spurs $50B Corporate Bond Surge As Tax Cut Optimism Drives Borrowing Costs To 25-Year Low - Caterpillar ( NYSE:CAT ) , Gilead Sciences ( NASDAQ:GILD ) 11/15/2024 10:56:00 AM
Companies rush to US bond market as Trump rally cuts borrowing costs 11/15/2024 5:00:00 AM
Brokers Suggest Investing in Gilead ( GILD ) : Read This Before Placing a Bet 11/14/2024 2:30:00 PM

Financial Details for GILD

Company Overview

Ticker GILD
Company Name Gilead Sciences Inc
Country USA
Description Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi.
Sector Name LIFE SCIENCES
Industry Name BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Most Recent Quarter 9/30/2024
Next Earnings Date 2/4/2025

Stock Price History

Last Day Price 88.15
Price 4 Years Ago 49.88
Last Day Price Updated 11/20/2024 4:07:39 PM EST
Last Day Volume 4,553,040
Average Daily Volume 6,484,081
52-Week High 98.90
52-Week Low 60.75
Last Price to 52 Week Low 45.10%

Valuation Measures

Trailing PE 975.00
Industry PE 120.49
Sector PE 40.32
5-Year Average PE 13.81
Free Cash Flow Ratio 21.82
Industry Free Cash Flow Ratio 15.59
Sector Free Cash Flow Ratio 27.97
Current Ratio Most Recent Quarter 1.26
Total Cash Per Share 4.04
Book Value Per Share Most Recent Quarter 14.83
Price to Book Ratio 5.92
Industry Price to Book Ratio 5.50
Sector Price to Book Ratio 20.88
Price to Sales Ratio Twelve Trailing Months 3.87
Industry Price to Sales Ratio Twelve Trailing Months 20.11
Sector Price to Sales Ratio Twelve Trailing Months 7.11
Analyst Buy Ratings 11
Analyst Strong Buy Ratings 7

Share Statistics

Total Shares Outstanding 1,246,270,000
Market Capitalization 109,858,700,500
Institutional Ownership N/A

Dividends

Ex-Dividend Date 12/13/2024
Last Dividend Amount 0.77
Current Dividend Amount 0.77
Total Years Dividend Increasing 9
Trailing Annual Dividend Rate 3.83
Trailing Annual Dividend Yield 4.34%
Forward Annual Dividend Rate 4.00
Forward Annual Dividend Yield 4.54%
5-Year Dividend Payments Count 21
3-Year Average Dividend Yield 3.67%
5-Year Average Dividend Yield 3.91%
1-Year Dividend Growth Rate Percentage 2.74%
3-Year Dividend Growth Rate Percentage 2.78%
5-Year Dividend Growth Rate Percentage 4.46%
All-Time Dividend Growth Rate Percentage 11.13%
Dividend Payout Ratio 4,255.56%

Income Statement

Quarterly Earnings Growth YOY -42.20%
Annual Earnings Growth 23.37%
Reported EPS 12 Trailing Months 0.09
Reported EPS Past Year 2.71
Reported EPS Prior Year 7.04
Net Income Twelve Trailing Months 126,000,000
Net Income Past Year 5,665,000,000
Net Income Prior Year 4,592,000,000
Quarterly Revenue Growth YOY 7.00%
5-Year Revenue Growth 3.46%
Operating Margin Twelve Trailing Months 0.42

Balance Sheet

Total Cash Most Recent Quarter 5,037,000,000
Total Cash Past Year 1,179,000,000
Total Cash Prior Year 6,385,000,000
Net Cash Position Most Recent Quarter -18,212,000,000
Net Cash Position Past Year -23,808,000,000
Long Term Debt Past Year 24,987,000,000
Long Term Debt Prior Year 25,229,000,000
Total Debt Most Recent Quarter 23,249,000,000
Equity to Debt Ratio Past Year 0.48
Equity to Debt Ratio Most Recent Quarter 0.44
Total Stockholder Equity Past Year 22,833,000,000
Total Stockholder Equity Prior Year 21,240,000,000
Total Stockholder Equity Most Recent Quarter 18,475,000,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months 4,565,000,000
Free Cash Flow Per Share Twelve Trailing Months 3.66
Free Cash Flow Past Year 7,421,000,000
Free Cash Flow Prior Year 8,344,000,000

Options

Put/Call Ratio 0.10
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 1.88
MACD Signal 2.28
20-Day Bollinger Lower Band 67.40
20-Day Bollinger Middle Band 81.52
20-Day Bollinger Upper Band 95.65
Beta 0.19
RSI 45.66
50-Day SMA 74.68
150-Day SMA 70.16
200-Day SMA 67.45

System

Modified 11/21/2024 1:55:44 AM EST